Zydus reports financial results for quarter ended June 30, 2026
The unaudited consolidated net profit after tax was INR 9,398 million, with total income from operations of INR 80,170 million for the quarter.
See the latest news and media coverage for Zydus. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global pharmaceutical company
zyduslife.comLast updated
In short: Zydus reported a Q1 FY27 profit decline despite revenue growth and finalized the $166 million acquisition of US-based Assertio Holdings.
The unaudited consolidated net profit after tax was INR 9,398 million, with total income from operations of INR 80,170 million for the quarter.
All nine resolutions were passed with requisite majority through remote e-voting and e-voting during the AGM.
Net profit declined 35.9% YoY, EBITDA margin fell to 24.1%, while acquisitions and a Sri Lanka JV were announced.
The Typhoid Conjugate Vaccine aims to support global immunisation efforts and improve access to life-saving vaccines for communities worldwide.
Zydus Lifesciences Ltd., with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life sciences...
Zydus undertakes not to commercially manufacture or launch Dabrafenib until Novartis' Indian patent expires in May 2029; statutory Bolar rights remain protected...
India's pharmaceutical market is showing signs of good health in 2026, after a relatively weak calendar year 2024 and 2025. In July 2026, sales jumped...
Zydus Lifesciences Ltd reported a 36% year-on-year decline in consolidated net profit to ₹939.8 crore for the first quarter of FY27, even as revenue from...
Track Zydus and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Zydus and other trending companies.